| Bioactivity | CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity[1]. | ||||||||||||
| Invitro | CA-5f (0-40 μM, 6 hour) concentration- and time-dependently elevates the level of LC3B-II (a marker to monitor autophagy) and SQSTM1 protein both in A549 cells and HUVECs[1].CA-5f (20 μM, 6 hours) inhibits the degradation of autophagosomes when treated alone or in combination Bafilomycin A1 (100 nM) or Chloroquine (30 μM) in A549 cells and HUVECs[1].CA-5f (20 μM) neither impairs the hydrolytic function nor the quantity of lysosomes[1].CA-5f (20 μM, 96 hours) inhibits the growth of A549 cells, and less cytotoxic to normal HUVECs[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | CA-5f | ||||||||||||
| CAS | 1370032-19-1 | ||||||||||||
| Formula | C24H24N2O3 | ||||||||||||
| Molar Mass | 388.46 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|